Vendors
日本語
search
  2. //
  3. Reports & insights
  4. //
  5. Unlocking the Opportunities of Cell and Gene Therapies

Unlocking the Opportunities of Cell and Gene Therapies

Create a vendor selection project
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
We are waiting for the vendor to publish their solution profile. Contact us or request the RFX.
Projects allow you to export Registered Vendor details and survey responses for analysis outside of Marsh CND. Please refer to the Marsh CND User Guide for detailed instructions.
Download Registered Vendor Survey responses as PDF
Contact vendor directly with specific questions (ie. pricing, capacity, etc)
8 June 2022

Editor's Note: The article was originally published in Brink.

Cell and gene therapies represent both the hopeful and the concerning sides of modern health care. They massively advance the science of medicine, treating and curing diseases that we struggled to address in the past. But they are also massively expensive and risk exacerbating inequities that already exist in the health care system. How do we unlock the opportunities of cell and gene therapies while avoiding the risks? Experts from Marsh McLennan Agency and Guy Carpenter weigh in.

Please click here for the remainder of the article